MRG 110
Alternative Names: Anti Mir92a; MRG-110; S95010Latest Information Update: 02 Jul 2024
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Servier; University of Texas Southwestern Medical Center; Viridian Therapeutics
- Class Anti-ischaemics; Cardiovascular therapies; Heart failure therapies; Ischaemic heart disorder therapies; MicroRNAs; Oligonucleotides
- Mechanism of Action MicroRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Heart failure; Ischaemia; Wounds
Most Recent Events
- 02 Jul 2024 Discontinued - Phase-I for Heart failure in USA (unspecified route) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
- 02 Jul 2024 Discontinued - Phase-I for Ischaemia (In volunteers, In adults) in USA (Intradermal) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)
- 02 Jul 2024 Discontinued - Phase-I for Wounds (In volunteers, In adults) in USA (Intradermal) prior to July 2024 (Viridian Therapeutics pipeline, July 2024)